trial

Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)

NCTId NCT00988728
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2012-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-02
Primary completion
2012-07
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
SCH 900435 (Org 25935)Olanzapine

Sponsors

Merck Sharp & Dohme LLCLead Sponsor

Sites

0 total

Linked catalysts

1
Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN) — primary completion2012-07

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE2
Primary Completion Date
2012-07
Status
WITHDRAWN
relationships
The graph out of here
drug
SCH 900435 (Org 25935)
drug
Olanzapine
drug
lead_sponsor
Merck Sharp & Dohme LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication